Kornimate/medical-research-clean huggingface dataset:
the alternative effects of electroacupuncture in the treatment of trigeminal neuralgia

Conditions: Trigeminal Neuralgia

Summary: trigeminal neuralgia (tn), characterized by its refractory nature and recurrence, frequently leads to anxiety, depression, and insomnia, thereby significantly diminishing patients' quality of life and potentially inducing self-harm. carbamazepine (cbz) is the first-line medication for tn, yet it presents adverse effects such as addiction and the absence of analgesic effects upon cessation. acupuncture, particularly electroacupuncture（ea）, has demonstrated efficacy in tn treatment, although its therapeutic outcomes are influenced by various factors. consequently, this study aims to evaluate the clinical efficacy of ea for tn and its potential as an alternative to cbz treatment.

this study will enroll a total of 148 patients with tn who meet the inclusion criteria. participants will be randomized in a 1:1 ratio to either the ea plus placebo group or the sham ea plus cbz group. this study aims to investigate the clinical efficacy of ea for tn and to determine if ea offers a viable therapeutic alternative for tn management.

Eligibility criteria:
inclusion criteria: * participants must meet all of the following criteria to be eligible for this study 1. met the diagnostic criteria for trigeminal neuralgia (tn) as defined in the international classification of headache disorders, 3rd edition (ichd-3) published by the international headache society (ihs) in 2018. 2. between 18 and 75 years old (inclusive), regardless of gender; 3. currently prescribed carbamazepine (100-300 mg/day) or oxcarbazepine (200-600 mg/day); 4. conscious, alert, and capable of perceiving/differentiating pain, with basic communication abilities; 5. signed informed consent form and voluntary participation in the study. exclusion criteria: * patients meeting any of the following criteria were excluded 1. patients with epilepsy, head injury, or other relevant neurological disorders; 2. patients with severe cardiac, hepatic, or renal impairment; 3. patients with cognitive dysfunction, aphasia, psychiatric disorders, or those unable to cooperate with treatment; 4. patients with poorly controlled hypertension or hyperglycemia; 5. patients with a recent diagnosis of severe anxiety or depression; 6. pregnant or breastfeeding patients;

Keywords: electroacupuncture randomized controlled trial
suprachoroidal injection of triamcinolone acetonide in subjects with macular edema following non-infectious uveitis

Conditions: Uveitis; Macular Edema; Uveitis, Posterior; Uveitis, Anterior; Panuveitis; Uveitis, Intermediate

Summary: the study is designed to evaluate the safety and efficacy of triamcinolone acetonide, cls-ta, in subjects with macular edema following non-infectious uveitis. a single suprachoroidal injection of one of two doses of cls-ta will each be evaluated in subjects with macular edema following non-infectious uveitis.

this is a phase 2, randomized, masked, multicenter study to assess the safety and efficacy of two different doses of cls-ta in the treatment of subjects with macular edema following non-infectious uveitis. each subject will receive a single suprachoroidal injection of cls-ta. the subjects enrolled in this study will be chosen from subjects with macular edema following non-infectious uveitis. a single injection will be administered via the clearside microinjector into the suprachoroidal space. the dose injected will either be 4 mg or 0.8 mg of cls-ta in a total volume of 100 μl. the dose they receive will depend on what their randomization code dictates. subjects will be monitored for safety and efficacy for approximately 8 weeks following treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of noninfectious uveitis * diagnosis of macular edema associated with noninfectious uveitis exclusion criteria: * any ocular trauma within the immediate 6 months prior to treatment * any photocoagulation or cryotherapy in the 6 months prior to treatment * any ivt injection of anti-vegf treatment in the 2 months prior to treatment * any eye diseases other than uveitis and me that could compromise central visual acuity * any previous suprachoroidal injection of triamcinolone acetonide in the study eye

Keywords: uveitis macular edema ume posterior uveitis anterior uveitis panuveitis intermediate uveitis noninfectious uveitis triamcinolone acetonide suprachoroidal space injection microneedle intravitreal injection corticosteroid cme choroid retina microinjection scs
study into genetic influence on cholesterol response to dietary fat

Conditions: Cardiovascular Diseases

Summary: cardiovascular disease (cvd) is recognised as one of the main causes of death in the western world. ldl- cholesterol ('bad' cholesterol) and other lipids (fats) are important cvd risk factors. apolipoprotein e (apoe) is an important transporter of fats in the blood. apoe comes in e2, e3 and e4 forms, depending on your genetic make up. approximately 60% of the uk population are e3/e3, 25% e4 carriers and 15% e2 carriers. there is some evidence to suggest that an e4 genotype may put you at modestly higher risk of cvd. furthermore although very inconclusive previous studies have suggested that e4 individuals are slightly more sensitive to the ldl-cholesterol modifying effects of dietary fats (saturated fat, total fat, fish oil) showing slightly, greater reductions when low levels of these fat are consumed, and greater increases when high levels of these fat are consumed. therefore, the aims of the satgene study is to examine the impact of modifications in dietary total fat and saturated fat intakes, alone and in combination with fish oil supplement on ldl-cholesterol and other blood lipids, in individuals with an e3 and e4 genotype. the levels of total fat and saturated fat used in the current study are within the range observed in a typical uk population.


Eligibility criteria:
inclusion criteria: men \& women 35-70 years bmi 20-32 kg/m2 haemoglobin (anaemia): 12.5-18.0g/l (men) and \> 11.5-16g/l (women) gamma gt (liver function) (\< 80 iu/l), triglyceride (between 1-4 mmol/l), plasma total cholesterol (4.5-8 mmol/l) glucose (world health organisation recommend \<7 mmol/l). exclusion criteria: * females who are breast feeding, may be pregnant, or if child-bearing potential are not taking effective contraceptive precautions * likely to alter oral contraceptive or hrt usage during the course of the study * blood pressure \> 160/100 mm hg (uk guidelines for stage 2 hypertension) * had suffered a myocardial infarction or stroke in the previous 12 months * hypertensive medication * diabetics type i and ii * any volunteers on a weight reducing diet, or vegan/vegetarians as study requires consumption of dairy products and fish oils * on high dose fish oil supplements (\> 1g epa + dha per day) * elevated lipids requiring medication such as statins, fibrates, gall bladder problems or other abnormalities of fat metabolism * subjects not willing to make the necessary dietary changes during the study * subjects drinking excessive alcohol (uk recommendations/wk currently for men are, no more than 21 units of alcohol per week or more than four units in any one day. for women, no more than 14 units of alcohol per week or more than three units per day). * subjects who train at a high level, or attend more than 3 hours organised exercise classes per week

Keywords: cvd, ldl-c, apoe, sfa, dha
self-directed online training for chinese caregivers

Conditions: Dementia; Alzheimer Disease

Summary: the proposed project seeks to develop an online self-directed learning (sdl) intervention program that seeks to improve caregiving and self-care skills among ethnic chinese dementia caregivers. the benefits of such a product may include improved psychological health in caregivers and a reduction in behavioral disturbances among elderly care recipients with dementia.

the objective of this phase ii application is to develop an online self-directed learning (sdl) intervention program that seeks to improve caregiving and self-care skills among ethnic chinese dementia caregivers. the benefits of such a product may include improved psychological health in caregivers and a reduction in behavioral disturbances among elderly care recipients with dementia. while online dementia caregiver interventions are advantageous in reaching broad audiences, these individuals face significant challenges in engaging the target audience and keeping them engaged throughout the intervention program. the proposed online sdl skill training intervention addresses these challenges with a comprehensive engagement design to ensure retention and effective learning in the training program. all phase i study aims have been successfully completed. the prototype provides preliminary evidence that an sdl training intervention is able to successfully engage ethnic chinese caregivers of elders with dementia, improving perceived self-efficacy to manage caregiving tasks, while reducing negative emotions in the caregiver. phase ii specific aims: the phase ii study will further develop the prototype into a fully-functioning online sdl skill training intervention for ethnic chinese dementia caregivers, and evaluate it in a randomized control trial. in specific aim 1, the research team will develop additional multi-lingual training video clips to complete the training program, and make them available for cantonese-, mandarin-, and/or english-speaking caregivers from different chinese cultural backgrounds. in specific aim 2, the research team will develop software that enables and integrates all engagement design functionalities. in specific aim 3, the research team will conduct a randomized controlled trial to evaluate the effectiveness of the sdl training intervention based on a comprehensive engagement design (intervention arm) compared to one that does not rely on a comprehensive engagement design (control arm). evidence of the effectiveness of the sdl intervention will contribute to the larger information and communication technology field, increasing the public's understanding and basic knowledge of effective engagement in the rapidly growing field of online health interventions. the comprehensive engagement approach developed through this research could be transferred to other ethnic minority groups facing dementia caregiving challenges, as well as other populations facing challenges related to the management of other chronic conditions.

Eligibility criteria:
inclusion criteria: * ethnic chinese caregiver exclusion criteria: * not chinese or caregiver
the eurocyst initiative: building a network of adpkd reference centers across europe

Conditions: Autosomal Dominant Polycystic Kidney Disease

Summary: eurocyst initiative aims to build a large, well-characterized cohort of autosomal dominant polycystic kidney disease (adpkd) subjects who are followed in a longitudinal observational cohort study has the potential to identify progression factors and biomarkers, and to assess disease stage specific mortality, morbidity and health care costs.

the eurocyst initiative aims to build a network of adpkd reference centers across europe and to establish a large-scale observational cohort of adpkd patients for the purpose of studying the pathogenesis, rate of disease progression, progression rate modifiers, disease stage specific morbidity, mortality, health economic issues and the predictive value of biomarkers in adpkd. overall 1,100 patients will be enrolled in 14 study sites across europe and will be followed up for at least three years. the adpkd reference center network across europe and the observational cohort study will enable european adpkd researchers to gain insight into the natural history, heterogeneity and associated complications of the disease as well as how it affects the lives of patients across europe.

Eligibility criteria:
inclusion criteria: * participants ≥ 18 years; * clinical diagnosis of adpkd based on kidney imaging and family history; * estimated glomerular filtration rate (egfr) ≥ 30 ml/min/1.73m2 (chronic kidney disease epidemiology collaboration(ckd-epi)- formula); * provided written informed consent. exclusion criteria: * receiving chronic renal replacement therapy before enrollment (dialysis, allograft) or anticipated in the following 12 months after enrollment; * participation in a clinical trial aiming to modify disease outcome one year or less before enrollment in the eurocyst study; * new york heart association (nyha) stadium iv.
ultrasound evaluation of laryngeal mask airway (lma) placement in pediatric patients and its relationship to postoperative complications

Conditions: Paediatric Airway

Summary: this study was designed to improve understanding of some respiratory reactions that can occur after surgery, such as difficulty breathing or persistent cough. these events, technically called prae (postoperative respiratory complications), are common reactions in children who have undergone surgery, and our aim is to find out if there are signs that can help us predict them, reducing their incidence in the future. during surgery, the child will receive general anesthesia, which will put him or her to sleep and not feel pain. in this context, a laryngeal mask airway (lma) will be used to help the child breathe. the laryngeal mask airway is a soft device that is placed in the throat and allows the airway to be kept open, making breathing possible. this is a standard tool that will be used during surgery regardless of participation in the study. the aim of this study is to better understand the relationship between the correct positioning of the laryngeal mask airway, measured by a specific ultrasound score, and the frequency of postoperative respiratory events in pediatric patients. as previously stated, these complications are common and well known in pediatric anesthesia practice, and the study aims to explore whether adequate ultrasound assessment can help predict and prevent them in the future. the study aims to observe the position of the laryngeal mask airway through a simple ultrasound and verify whether there is a relationship between the way the mask is positioned and the possibility of postoperative respiratory events. this type of ultrasound is non-invasive and does not add risk to the child. this ultrasound check will take place without affecting the normal treatment of the patient and does not involve any additional risk or discomfort. the study is purely observational: this means that we will collect information without modifying in any way the care already foreseen for the child. the laryngeal mask airway and neck ultrasound are already part of standard medical practice, and the study does not present any additional risks. in this case, it is only a matter of reporting in all children who will participate in the study the "results" of ecological story of the neck (which we will process according to a score) and to evaluate whether there is a relationship between this score and the occurrence of respiratory adverse events upon awakening. the overall duration of the study is 24 months. in total, we expect to include about 340 patients.


Eligibility criteria:
inclusion criteria: * patients undergoing surgery under general anesthesia with laryngeal mask airway placement. exclusion criteria: * patients without the need for invasive airway management or undergoing surgery requiring orotracheal intubation. * patients with known craniofacial malformations. * patients undergoing neck surgery.
vitamins d and k effects on vascular function in obese adults.

Conditions: Obesity; Vitamin D3 Deficiency

Summary: a prospective, randomized, placebo-controlled, double-blind study that aims to evaluate the effects of combined vitamin d3 and k2-mk7 supplementation on vascular function, sympathetic tone, metabolic biomarkers and inflammatory factors in a population of overweight or obese adults and deficient or insufficient serum levels of vitamin d.

overweight and obesity are public health issues of epidemic proportions nowadays. they constitute risk factors for several chronic diseases with vascular, metabolic, and inflammatory changes. adequate serum levels of vitamin d are correlated with good cardiovascular and metabolic health, since its deficiency and insufficiency (highly prevalent in obesity) have an inverse correlation. likewise, vitamin k, especially k2, is related to the reduction of arterial stiffness, suppression of the inflammation in the vascular wall, favorable action on the lipid profile, whereas insufficiency is related to increased cardiovascular risk. the combined use of vitamin d and k aiming to reduce cardiovascular risk has been studied, however, the results of randomized clinical trials are still controversial. this prospective, randomized, placebo-controlled, double-blind trial aims to evaluate the effect of supplementation of vitamins d3 and k2-mk7 on vascular function, sympathetic tone, metabolic biomarkers and inflammatory factors in a population of overweight or obese adults and serum levels of deficient or insufficient vitamin d. individuals of both sexes, aged between 40 and 70 years, body mass index (bmi) ≥ 25 and \< 40 kg/m² and vitamin 25ohd3 \<30 ng/ml will be randomized into 3 groups (a/b/c) to receive supplementation (placebo/vitd3 7000 iu/vitd3 7000iu+k2-mk7-180mcg) daily for 16 weeks. individuals will be rated at 4 visits namely: * v0 screening according to inclusion and exclusion criteria; clinical, anthropometry and electrical bioimpedance, laboratory and vascular evaluation before supplementation; * v1 supplementation begins; * v2 after 8 weeks; * v3 at the end of the intervention. the laboratory evaluation consists of blood count, biochemistry, electrolytes, glucose, lipid, liver and thyroid profiles, vitamin d3 and parathyroid hormone, in addition to the urinary excretion of calcium and creatinine. sympathetic tone is assessed by a frequency meter (polar® verity sense), arterial stiffness by measuring the pulse wave velocity by oscillometry (mobil-o-graph®) and endothelium function by measuring post-occlusion microvascular reactivity using laser speckle contrast image-lsci.

Eligibility criteria:
inclusion criteria: * vitamin d deficiency; * vitamin d insufficiency; * obesity; * overweight; exclusion criteria: * diabetes mellitus; * arterial coronary disease; * beta blocker use; * cancer; * esrd;

Keywords: obesity vitamin d3 deficiency vitamin k sympathetic tonus endothelial dysfunction arterial stiffness
ovarian tissue cryopreservation in females undergoing procedures that will potentially lead to loss of ovarian function

Conditions: Cancer; Effects of Chemotherapy; Unspecified Complication of Bone Marrow Transplant; Auto Immune Disease

Summary: the purpose of this study is to retrieve and cryopreserve ovarian tissue from females undergoing a treatment that may lead to irreversible loss of ovarian function.

the aim of this preliminary study is to retrieve and properly cryopreserve ovarian tissue for autotransplantation in any premenopausal female whose ovarian function is threatened in a physiological, pathological or iatrogenic manner in an effort to observe the return of ovarian endocrine function and development of egg(s) appropriate for use in in vitro fertilization.

Eligibility criteria:
inclusion criteria: * patient must be female. * patient must have a disease process where the disease or its treatment adversely affects ovarian function. * patient must be recommended for this study by their oncologist or specialist. * patient (or legally authorized representative) must sign an informed consent. exclusion criteria: * patients cannot be male. * patients must not be hiv positive. * patient cannot have a poor diagnosis such that she is not expected to survive to adulthood. * patient cannot have any medical condition that would contraindicate surgery. * patient cannot have any medical condition that would contraindicate general anesthesia. * patient cannot have any medical condition that would contraindicate pregnancy.

Keywords: cancer cryopreservation ovarian function in vitro
immunosuppressive therapy with certican (everolimus) after lung transplantation

Conditions: Lung Transplantation

Summary: the purpose of this study is to determine whether everolimus is effective in the treatment and prevention of chronic graft dysfunction and chronic graft rejection after lung transplantation.


Eligibility criteria:
inclusion criteria: * recipient of single or bilateral lung transplantation * informed consent * recipients who are able to receive everolimus at week 3 after lung transplantation * women of childbearing potential must have a negative pregnancy test within 48 hours of enrolment * women of childbearing potential must use appropriate contraceptive method at enrolment, during the study and up to 8 weeks after the end of the study * donor must not have relevant pulmonary diseases * donor must have oxygen partial pressure higher than 300 mmhg at fio 1.0 and positive end-expiratory pressure of 5 cm h2o. exclusion criteria: * systemic infection of the donor * donor: signs or symptoms of aspiration * donor: severe pulmonary injury or contusion * donor: malignant neoplasm of the lung * donor: hiv positive * recipients who receive immunosuppressive agents not used in this protocol * recipients who participated within 30 days before study start or are currently participating in another investigational drug trial * hiv positive recipient * systemic infection of the recipient * recipients of combined/ multiple transplantations * pregnancy of the recipient * recipients with signs/ symptoms of impaired wound healing of the pulmonary anastomoses * recipients who are still on artificial respiration or who are not able to swallow tablets at week 3 after transplantation

Keywords: lung transplantation immunosuppression mortality graft rejection bronchiolitis obliterans opportunistic infections nephrotoxicity